Loading...
XJPX
4151
Market cap7.44bUSD
Apr 08, Last price  
2,076.00JPY
1D
0.14%
1Q
-10.29%
Jan 2017
28.47%
Name

Kyowa Kirin Co Ltd

Chart & Performance

D1W1MN
P/E
18.15
P/S
2.19
EPS
114.40
Div Yield, %
2.79%
Shrs. gr., 5y
-0.35%
Rev. gr., 5y
10.14%
Revenues
495.56b
+12.06%
353,440,000,000354,274,000,000392,120,000,000460,183,000,0000413,738,000,000343,722,000,000333,158,000,000340,611,000,000333,446,000,000364,316,000,000343,019,000,000353,380,000,000346,531,000,000305,820,000,000318,352,000,000352,246,000,000398,371,000,000442,233,000,000495,558,000,000
Net income
59.87b
-26.26%
16,273,000,00012,694,000,00023,477,000,00011,726,000,000022,197,000,00025,608,000,00024,199,000,00030,078,000,00015,898,000,00029,774,000,00018,669,000,00042,899,000,00054,414,000,00037,674,000,00047,027,000,00052,347,000,00053,573,000,00081,188,000,00059,870,000,000
CFO
67.88b
-41.25%
30,104,000,00014,303,000,00023,381,000,00030,714,000,00041,069,000,00064,189,000,00040,634,000,00059,134,000,00056,884,000,00019,377,000,00066,526,000,00065,752,000,00064,903,000,00056,181,000,00053,657,000,00039,501,000,00086,546,000,00048,672,000,000115,551,000,00067,884,000,000
Dividend
Jun 27, 20250 JPY/sh
Earnings
May 05, 2025

Profile

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
URL
https://www.kyowakirin.co.jp/
IPO date
Aug 22, 1949
Employees
5,982
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
495,558,000
12.06%
442,233,000
11.01%
398,371,000
13.09%
Cost of revenue
403,692,000
346,391,000
363,329,000
Unusual Expense (Income)
NOPBT
91,866,000
95,842,000
35,042,000
NOPBT Margin
18.54%
21.67%
8.80%
Operating Taxes
23,583,000
16,058,000
14,000,000
Tax Rate
25.67%
16.75%
39.95%
NOPAT
68,283,000
79,784,000
21,042,000
Net income
59,870,000
-26.26%
81,188,000
51.55%
53,573,000
2.34%
Dividends
(30,895,000)
(29,027,000)
(25,258,000)
Dividend yield
2.46%
2.28%
1.56%
Proceeds from repurchase of equity
(40,014,000)
(10,000)
(11,000)
BB yield
3.18%
0.00%
0.00%
Debt
Debt current
5,729,000
Long-term debt
31,827,000
34,451,000
Deferred revenue
(16,902,000)
Other long-term liabilities
51,877,000
40,143,000
66,826,000
Net debt
(249,571,000)
(418,910,000)
(335,545,000)
Cash flow
Cash from operating activities
67,884,000
115,551,000
48,672,000
CAPEX
(26,037,000)
(17,213,000)
(28,666,000)
Cash from investing activities
(142,387,000)
(20,382,000)
(17,185,000)
Cash from financing activities
(84,697,000)
(32,535,000)
(29,032,000)
FCF
35,714,000
91,999,000
(9,251,000)
Balance
Cash
246,386,000
405,006,000
339,720,000
Long term investments
3,185,000
45,731,000
36,005,000
Excess cash
224,793,100
428,625,350
355,806,450
Stockholders' equity
397,795,000
374,620,000
312,587,000
Invested Capital
677,894,900
517,657,000
521,212,000
ROIC
11.42%
15.36%
4.03%
ROCE
10.18%
10.74%
4.20%
EV
Common stock shares outstanding
529,557
537,635
537,570
Price
2,375.50
0.23%
2,370.00
-21.52%
3,020.00
-3.67%
Market cap
1,257,962,518
-1.27%
1,274,193,820
-21.51%
1,623,462,176
-3.66%
EV
1,008,391,518
855,283,820
1,298,935,176
EBITDA
116,646,000
116,938,000
53,518,000
EV/EBITDA
8.64
7.31
24.27
Interest
7,538,000
190,000
1,088,000
Interest/NOPBT
8.21%
0.20%
3.10%